-->

Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Net Income
(77,211)
(117,042)
(630,210)
(171,799)
Operating Activities, Cash Flows Provided By or Used In
Depreciation
--
87,861
96,912
47,187
Changes In Accounts Receivables
--
(25,256)
(51,483)
(16,367)
Changes In Assets and Liabilities
--
(93,963)
(160,276)
46,332
Changes In Inventories
--
(96,890)
(64,512)
(50,989)
Changes In Other Operating Activities
77,211
236,533
581,732
(76,053)
Total Cash Flow From Operating Activities
--
(8,757)
(227,837)
(221,689)
Investing Activities, Cash Flows Provided By or Used In
Capital Expenditures
(102,541)
(199,219)
(148,380)
(227,653)
Investments
--
(229,487)
(332,180)
(451,797)
Other Cash flows from Investing Activities
102,541
123,247
(3,487)
(500,148)
Total Cash Flows From Investing Activities
--
(305,459)
(484,047)
(1,179,598)
Financing Activities, Cash Flows Provided By or Used In
Dividends Paid
--
--
--
--
Sale/Purchase of Stock
--
--
712,938
888,257
Net Borrowings
--
481,713
--
--
Other Cash Flows from Financing Activities
--
25,432
14,170
39,656
Total Cash Flows From Financing Activities
--
507,145
727,108
927,913
Effect Of Exchange Rate Changes
--
(3,231)
(3,934)
(5,072)
Change In Cash and Cash Equivalents
--
192,929
11,290
(478,446)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information